Global Economic Sentiment and Investment in High-Risk Assets: The IMF's downgraded global growth forecasts and geopolitical instability (Middle East conflict) can lead to a risk-off environment, reducing investor appetite for clinical-stage biotechnology companies like Alpha Tau Medical that typically require significant capital and have no current revenue.

Healthcare Industry Regulatory Landscape (FDA/Global Approvals): As a clinical-stage oncology company, DRTS's success is heavily dependent on regulatory approvals for its Alpha DaRT technology. The overall stringency, speed, and cost of regulatory processes (e.g., FDA in the US, or Japanese approval already received) significantly impact its operational milestones and market potential.

Competition and Innovation in Oncology: The oncology therapeutic space is highly competitive with continuous innovation. DRTS's Alpha DaRT therapy must demonstrate superior efficacy and safety compared to existing and pipeline treatments to gain market share, influencing its long-term viability and investor confidence.